K.R. Harrap

2.0k total citations
31 papers, 1.2k citations indexed

About

K.R. Harrap is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, K.R. Harrap has authored 31 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 14 papers in Oncology and 10 papers in Organic Chemistry. Recurrent topics in K.R. Harrap's work include Biochemical and Molecular Research (12 papers), Cancer Treatment and Pharmacology (5 papers) and Enzyme function and inhibition (4 papers). K.R. Harrap is often cited by papers focused on Biochemical and Molecular Research (12 papers), Cancer Treatment and Pharmacology (5 papers) and Enzyme function and inhibition (4 papers). K.R. Harrap collaborates with scholars based in United Kingdom, Hungary and United States. K.R. Harrap's co-authors include Robert Jackson, A H Calvert, Ann L. Jackman, Terence R. Jones, David R. Newell, J.H. Goldie, L A Price, Mark Jones, T.A. Connors and CF O'Neill and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Annals of the New York Academy of Sciences.

In The Last Decade

K.R. Harrap

30 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K.R. Harrap United Kingdom 18 574 523 219 153 130 31 1.2k
R G Moran United States 18 878 1.5× 352 0.7× 122 0.6× 160 1.0× 55 0.4× 28 1.3k
Barbara A. Moroson United States 20 943 1.6× 546 1.0× 131 0.6× 296 1.9× 73 0.6× 35 1.7k
Arlene R. Cashmore United States 22 721 1.3× 243 0.5× 139 0.6× 269 1.8× 40 0.3× 35 1.3k
Lynn S. Gossett United States 10 475 0.8× 381 0.7× 148 0.7× 74 0.5× 35 0.3× 13 943
Juerg Zimmermann Switzerland 7 716 1.2× 356 0.7× 581 2.7× 53 0.3× 90 0.7× 10 1.6k
Karen G. Louie United States 9 1.0k 1.8× 672 1.3× 163 0.7× 97 0.6× 162 1.2× 12 1.7k
Louis J. Lombardo United States 22 548 1.0× 252 0.5× 567 2.6× 130 0.8× 58 0.4× 54 1.7k
Edvardas Kaminskas United States 20 1.2k 2.1× 405 0.8× 78 0.4× 140 0.9× 100 0.8× 33 2.1k
Susan M. Ludeman United States 20 593 1.0× 387 0.7× 193 0.9× 215 1.4× 226 1.7× 51 1.4k
Schabel Fm United States 23 766 1.3× 941 1.8× 169 0.8× 164 1.1× 155 1.2× 60 2.1k

Countries citing papers authored by K.R. Harrap

Since Specialization
Citations

This map shows the geographic impact of K.R. Harrap's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K.R. Harrap with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K.R. Harrap more than expected).

Fields of papers citing papers by K.R. Harrap

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K.R. Harrap. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K.R. Harrap. The network helps show where K.R. Harrap may publish in the future.

Co-authorship network of co-authors of K.R. Harrap

This figure shows the co-authorship network connecting the top 25 collaborators of K.R. Harrap. A scholar is included among the top collaborators of K.R. Harrap based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K.R. Harrap. K.R. Harrap is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Harrap, K.R. & Robert Jackson. (2015). Biochemical Mechanisms of Resistance to Antimetabolites. Antibiotics and chemotherapy/Antibiotica et chemotherapia. 23. 228–237.
2.
Clarke, Stephen, M. de Boer, Jaco J. Verweij, et al.. (1996). Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors.. Journal of Clinical Oncology. 14(5). 1495–1503. 67 indexed citations
3.
Harrap, K.R.. (1995). Initiatives with platinum- and quinazoline-based antitumor molecules--Fourteenth Bruce F. Cain Memorial Award Lecture.. PubMed. 55(13). 2761–8. 45 indexed citations
4.
McKeage, Mark J., et al.. (1994). Lack of neurotoxicity of oral bisacetatoamminedichlorocyclohexylamine-platinum(IV) in comparison to cisplatin and tetraplatin in the rat.. PubMed. 54(3). 629–31. 36 indexed citations
5.
6.
Orr, Rosanne M., CF O'Neill, MC Nicolson, et al.. (1994). Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin. British Journal of Cancer. 70(3). 415–420. 17 indexed citations
7.
Ormerod, M.G., CF O'Neill, David Robertson, & K.R. Harrap. (1994). Cisplatin Induces Apoptosis in a Human Ovarian Carcinoma Cell Line without Concomitant Internucleosomal Degradation of DNA. Experimental Cell Research. 211(2). 231–237. 111 indexed citations
8.
Mistry, Prakash & K.R. Harrap. (1991). Historical aspects of glutathione and cancer chemotherapy. Pharmacology & Therapeutics. 49(1-2). 125–132. 34 indexed citations
9.
Harrap, K.R., Ann L. Jackman, David R. Newell, et al.. (1989). Thymidylate synthase: A target for anticancer drug design. Advances in Enzyme Regulation. 29. 161–179. 44 indexed citations
10.
Jones, Terence R., AH Calvert, A.L. Jackman, et al.. (1986). ChemInform Abstract: Quinazoline Antifolates Inhibiting Thymidylate Synthase: Variation of the N10 Substituent.. Chemischer Informationsdienst. 17(6). 3 indexed citations
11.
Muindi, Josephia R., David R. Newell, I. E. Smith, & K.R. Harrap. (1983). Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies. British Journal of Cancer. 47(1). 27–33. 9 indexed citations
12.
Newell, David R., et al.. (1982). The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse. Cancer Chemotherapy and Pharmacology. 8(1). 105–111. 19 indexed citations
13.
Harrap, K.R., Terence R. Jones, A H Calvert, & A L Jackman. (1980). A potent quinazoline inhibitor of thymidylate synthetase (ts) possessing significant antitumour activity in animals. Abstr.. The Mouseion at the JAXlibrary (Jackson Laboratory). 259. 3 indexed citations
14.
Calvert, A H, Terence R. Jones, P J Dady, et al.. (1980). Quinazoline antifolates with dual biochemical loci of action. Biochemical and biological studies directed towards overcoming methotrexate resistance. European Journal of Cancer (1965). 16(5). 713–722. 32 indexed citations
15.
Browman, George P., A. Hilary Calvert, G. A. Taylor, L. I. Hart, & K.R. Harrap. (1980). The intracellular mechanism of action of metoprine (DDMP). European Journal of Cancer (1965). 16(12). 1547–1554. 4 indexed citations
16.
Connors, T.A., M. J. Cleare, & K.R. Harrap. (1980). Structure-activity relationships of the antitumor platinum coordination complexes.. PubMed. 63(9-10). 1499–502. 44 indexed citations
17.
Talbot, D C, et al.. (1977). Some Observations on the Reversibility of Methotrexate Toxicity in Normal Proliferating Tissues2. JNCI Journal of the National Cancer Institute. 58(1). 91–97. 22 indexed citations
18.
Goldie, J.H., L A Price, & K.R. Harrap. (1972). Methotrexate toxicity: Correlation with duration of administration, plasma levels, dose and excretion pattern. European Journal of Cancer (1965). 8(4). 409–414. 112 indexed citations
19.
Harrap, K.R., et al.. (1971). SITES OF ACTION OF AMETHOPTERIN: INTRINSIC AND ACQUIRED DRUG RESISTANCE. Annals of the New York Academy of Sciences. 186(1 Folate Antago). 312–324. 1 indexed citations
20.
Bergel, F. & K.R. Harrap. (1965). Future possibilities for the development of treatments of leukemia.. PubMed. 25(9). 1643–8. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R G Moran Breakdown of academic impact, for papers by Barbara A. Moroson Breakdown of academic impact, for papers by Arlene R. Cashmore Breakdown of academic impact, for papers by Lynn S. Gossett Breakdown of academic impact, for papers by Juerg Zimmermann Breakdown of academic impact, for papers by Karen G. Louie Breakdown of academic impact, for papers by Louis J. Lombardo Breakdown of academic impact, for papers by Edvardas Kaminskas Breakdown of academic impact, for papers by Susan M. Ludeman Breakdown of academic impact, for papers by Schabel Fm
Rankless by CCL
2026